• Science
  • Pipeline
  • About Us
  • News & Media
  • Resources
  • Investors
  • Contact Us
  • Science
  • Pipeline
  • About Us
  • News & Media
  • Resources
  • Investors
  • Contact Us
Mobile close button Mobile toggle button

Sitemap

Pages

  • About Us
  • Aim Rule 26
  • Contact Us
  • Governance
  • Home
  • Investors
  • News & Media
  • Pipeline
  • Privacy Policy
  • Resources
  • Science
  • Sitemap

News

  • Evgen Pharma “cash runway in pretty good shape”
  • Evgen Pharma Encouraging interim data from the STEM trial
  • Evgen Pharma have ‘many shots at goal’, solving unmet needs in the pharmaceutical industry
  • Evgen Pharma Licensing and Clinical Programme Update
  • Evgen Pharma makes progress on two fronts in the field of cancer
  • Evgen Pharma now has the financial runway to exploit its technology after ‘transformative’ City fundraiser
  • Evgen Pharma Post AGM Presentation
  • Evgen Pharma presents 2022 clinical trials plans and progress with US and UK regulators
  • Evgen Pharma talks through clinical milestones and financial results from its 2022 full-year report
  • Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug
  • Evgen Pharma: Johns Hopkins research further assesses the potential of company’s drug to treat COVID-19
  • Evgen portfolio update on core field of cancer, ‘the R&D is entirely on plan and on budget’
  • Going for Growth: Evgen Pharma CEO, Huw Jones, interviewed by ShareBuyers
  • Interim Results 2022-23
Copyright© 2023
  • Privacy Policy
  • Sitemap
Twitter Twitter linkedin linkedin
Get in touch